MSDS for CHLORPYRIFOS

            MATERIAL SAFETY DATA SHEET            PST04910     Page 001 of 010

------------------------------------------------------------------------------
| SECTION 1       CHEMICAL PRODUCTS & COMPANY IDENTIFICATION                 |
------------------------------------------------------------------------------
MDL INFORMATION SYSTEMS, INC.                 FOR EMERGENCY SOURCE INFORMATION
14600 CATALINA STREET                         CONTACT: 1-615-366-2000 USA
SAN LEANDRO, CA 94577
1-800-635-0064   OR
1-510-895-1313
                                                   CAS NUMBER: 2921-88-2
                                                   RTECS NUMBER: TF6300000
SUBSTANCE: CHLORPYRIFOS

TRADE NAMES/SYNONYMS:
PHOSPHOROTHIOIC ACID, O,O-DIETHYL O-(3,5,6-TRICHLORO-2-PYRIDINYL)
ESTER;
PHOSPHOROTHIOIC ACID, O,O-DIETHYL O-(3,5,6-TRICHLORO-2-PYRIDYL) ESTER;
O,O-DIETHYL O-3,5,6-TRICHLORO-2-PYRIDYL PHOSPHOROTHIOATE;
O,O-DIETHYL O-(3,5,6-TRICHLORO-2-PYRIDYL) PHOSPHOROTHIOATE;
O,O-DIETHYL O-(3,5,6-TRICHLORO-2-PYRIDINYL) PHOSPHOROTHIOATE;
DIETHYL 3,5,6-TRICHLORO-2-PYRIDYL PHOSPHOROTHIONATE; CHLOROPYRIPHOS;
CHLOROPYRIFOS; CHLORPYRIPHOS; CORBAN; DOWCO 179; DURSBAN; KILLMASTER;
LORSBAN; OMS 971; ENT 27311; STCC 4941124; C9H11CL3NO3PS; PST04910

CHEMICAL FAMILY:
Organophosphate
Halogen compound, aromatic

           CREATION DATE: 10/04/89          REVISION DATE: 06/30/94
------------------------------------------------------------------------------
| SECTION 2        COMPOSITION/INFORMATION ON INGREDIENTS                    |
------------------------------------------------------------------------------

COMPONENT : CHLORPYRIFOS
CAS NUMBER: 2921-88-2
PERCENTAGE: 100

------------------------------------------------------------------------------
| SECTION 3                HAZARDS IDENTIFICATION                            |
------------------------------------------------------------------------------

CERCLA RATINGS (SCALE 0-3):  HEALTH=3  FIRE=U  REACTIVITY=1  PERSISTENCE=3
NFPA RATINGS (SCALE 0-4):  HEALTH=3  FIRE=U  REACTIVITY=1

EMERGENCY OVERVIEW:
White crystalline solid with a mild mercaptan odor
  Harmful if swallowed. Causes skin and eye irritation. May affect the nervous
  system. May cause convulsions. May affect the central nervous system.
  Containers may violently rupture at elevated temperatures.
  Keep away from heat and flame. Avoid breathing dust. Avoid contact with
  eyes, skin and clothing. Keep container tightly closed. Wash thoroughly
  after handling. Use only with adequate ventilation. Handle with caution.

POTENTIAL HEALTH EFFECTS:
INHALATION:
  SHORT TERM EFFECTS: May cause coughing, nose bleed, paleness, sweating,
  tearing, drooling, nausea, vomiting, diarrhea, stomach pain, involuntary






                                                  PST04910     Page 002 of 010


  defecation and/or urination, difficulty speaking, chest pain, difficulty
  breathing, headache, weakness, dizziness, confusion, loss of reflexes,
  twitching, mental disorders, blurred vision, dilated pupils or pin-point
  pupils, bluish skin color, lung congestion, paralysis, convulsions,
  unconsciousness, coma and heart failure.
  LONG TERM EFFECTS: In addition to effects from short term exposure, lack of
  appetite, speech disorders, drowsiness, disorientation, sleeplessness and
  loss of memory may occur.

SKIN CONTACT:
  SHORT TERM EFFECTS: May cause irritation. Additional effects may include
  sweating and twitching.
  LONG TERM EFFECTS: May cause effects as reported in short term exposure.

EYE CONTACT:
  SHORT TERM EFFECTS: May cause irritation. Additional effects may include
  tearing, twitching of the eyelid, muscle spasm and dilated pupils or
  pin-point pupils.
  LONG TERM EFFECTS: May cause effects as reported in short term exposure.

INGESTION:
  SHORT TERM EFFECTS: May cause lack of appetite, nausea, vomiting, diarrhea
  and stomach pain. May also cause reproductive effects.
  LONG TERM EFFECTS: May cause effects as reported in short term exposure.

CARCINOGEN STATUS:
OSHA: N
NTP:  N
IARC: N

------------------------------------------------------------------------------
| SECTION 4                  FIRST AID MEASURES                              |
------------------------------------------------------------------------------

INHALATION:
FIRST AID- Remove from exposure area to fresh air immediately. Perform
  artificial respiration if necessary. Maintain airway, blood pressure and
  respiration. Keep warm and at rest. Treat symptomatically and supportively.
  Get medical attention immediately. Qualified medical personnel should
  consider administering oxygen.

SKIN CONTACT:
FIRST AID- Remove contaminated clothing immediately. Wash contaminated areas
  with soap and water followed by alcohol (Arena, Poisoning, 4th Ed.).
  Emergency personnel should wear gloves and avoid contamination. Treat
  respiratory difficulty with artificial respiration. Get medical
  attention immediately.

EYE CONTACT:
FIRST AID- Irrigate eyes with water or saline solution. If symptoms of
  poisoning occur, treat respiratory difficulty with artificial respiration
  and oxygen. Observe patient for at least 24-36 hours (Gosselin, Clinical
  Toxicology of Commercial Products, 5th Ed.). Get medical attention
  immediately. Oxygen should be administered by qualified medical personnel.

INGESTION:
FIRST AID- If person is alert and respiration is not depressed, give syrup of
  ipecac followed by water (if vomiting occurs, keep head below hips to
  prevent aspiration). If consciousness level declines or vomiting has not
  occurred in 15 minutes empty stomach by gastric lavage with the aid of
  cuffed endotracheal tube using isotonic saline or 5% sodium bicarbonate

                                                  PST04910     Page 003 of 010

  follow with activated charcoal. Establish and maintain airway. Treat
  respiratory difficulty with artificial respiration and oxygen. Do not give
  morphine, aminophylline, phenothiazines, reserpine, furosemide, or
  ethacrynic acid (Morgan, Recognition and Management of Pesticide Poisonings,
  3rd Ed.). Treat symptomatically and supportively. Administration of oxygen
  and lavage must be performed by qualified medical personnel. Get medical
  attention immediately.

NOTE TO PHYSICIAN

ANTIDOTE:
The following antidote(s) have been recommended. However, the decision as to
whether the severity of poisoning requires administration of any antidote and
actual dose required should be made by qualified medical personnel.

FOR CHOLINESTERASE INHIBITORS:
Establish clear airway and tissue oxygenation by aspiration of secretions, and
if necessary, by assisted pulmonary ventilation with oxygen. Improve tissue
oxygenation as much as possible before administering atropine to minimize the
risk of ventricular fibrillation. Administer atropine sulfate intravenously,
or intramuscularly if iv injection is not possible. In moderately severe
poisoning administer atropine sulfate, 0.4-2.0 mg repeated every 15 minutes
until atropinization is achieved (tachycardia, flushing, dry mouth,
mydriasis). Maintain atropinization by repeated doses for 2-12 hours, or
longer, depending on the severity of poisoning. The appearance of rales in
the lung bases, miosis, salivation, nausea, bradycardia, are all indications
of inadequate atropinization. Severely poisoned individuals may exhibit
remarkable tolerance to atropine; two or more times the dosages suggested
above may be needed. Persons not poisoned or only slightly poisoned,
however, may develop signs of atropine toxicity from such large dosages:
Fever, muscle fibrillations, and delirium are the main signs of atropine
toxicity. If these signs appear while the patient is fully atropinized,
atropine administration should be discontinued, at least temporarily.
Observe treated patients closely at least 24 hours to insure that symptoms
(possibly pulmonary edema) do not recur as atropinization wears off. In very
severe poisonings, metabolic disposition of toxicant may require several hours
or days during which atropinization must be maintained. Markedly lower levels
of urinary metabolites indicate that atropine dosage can be tapered off. As
dosage is reduced, check the lung bases frequently for rales. If rales are
heard or other symptoms return, re-establish atropinization promptly
(Morgan, Recognition and Management of Pesticide Poisonings, 3rd Ed.).
Administration of antidote must be performed by qualified medical personnel.
In cases of severe poisoning by organophosphate pesticides in which
respiratory depression, muscle weakness and twitchings are severe, give
pralidoxime (Protopam-Ayerst, 2-PAM), 1.0 gram intravenously at no more
than 0.5 gram per minute. Dosage of pralidoxime may be repeated in 1-2 hours,
then at 10-12 hour intervals if needed. In very severe poisonings, dosage
rates may be doubled. Treatment with pralidoxime will be most effective if
given within thirty-six hours after poisoning (Morgan, Recognition and
Management of Pesticide Poisonings, 3rd Ed.). Antidote should be administered
by qualified medical personnel.












                                                  PST04910     Page 004 of 010

------------------------------------------------------------------------------
| SECTION 5                FIRE FIGHTING MEASURES                            |
------------------------------------------------------------------------------

FIRE AND EXPLOSION HAZARD:
Unknown fire and explosion hazard.

EXTINGUISHING MEDIA:
Dry chemical, water spray or regular foam
(1993 Emergency Response Guidebook, RSPA P 5800.6).
For larger fires, use water spray, fog or regular foam
(1993 Emergency Response Guidebook, RSPA P 5800.6).

FIREFIGHTING:
Move container from fire area if you can do it without risk. Fight fire from
maximum distance. Stay away from ends of tanks. Dike fire-control water for
later disposal; do not scatter the material (1993 Emergency Response
Guidebook, RSPA P 5800.6, Guide Page 55).
Extinguish only if flow can be stopped; use flooding amounts of water as fog,
solid streams may be ineffective. Cool containers with flooding amounts of
water from as far a distance as possible. Use water spray to absorb toxic
vapors. Avoid breathing toxic vapors; keep upwind. Consider evacuation of
downwind area if material is leaking.

HAZARDOUS COMBUSTION PRODUCTS:
Thermal decomposition may release toxic and/or hazardous gases.

------------------------------------------------------------------------------
| SECTION 6             ACCIDENTIAL RELEASE MEASURES                         |
------------------------------------------------------------------------------

OCCUPATIONAL SPILL:
Do not touch spilled material. Stop leak if you can do it without risk. Use
water spray to reduce vapors. For small spills, take up with sand or other
absorbent material and place into containers for later disposal. For small
dry spills, with a clean shovel place material into clean, dry containers and
cover. Move containers from spill area. For larger spills, dike far ahead of
spill for later disposal. Keep unnecessary people away. Isolate hazard area
and deny entry. Ventilate closed spaces before entering.
Reportable Quantity (RQ): 1 pound
The Superfund Amendments and Reauthorization Act (SARA) Section 304 requires
that a release equal to or greater than the reportable quantity for this
substance be immediately reported to the local emergency planning committee
and the state emergency response commission (40 CFR 355.40). If the release of
this substance is reportable under CERCLA Section 103, the National Response
Center must be notified immediately at (800) 424-8802 or (202) 426-2675 in the
metropolitan Washington, D.C. area (40 CFR 302.6).

SOIL SPILL:
Dig holding area such as lagoon, pond or pit for containment.
Use protective cover such as a plastic sheet to prevent material from
dissolving in fire extinguishing water or rain.

WATER SPILL:
Trap spilled material at bottom in deep water pockets, excavated holding areas
or within sand bag barriers.






                                                  PST04910     Page 005 of 010

Use activated carbon to absorb spilled substance that is dissolved.
Use suction hoses to remove trapped spill material.
Use mechanical dredges or lifts to extract immobilized masses of pollution and
precipitates.

------------------------------------------------------------------------------
| SECTION 7                 HANDLING AND STORAGE                             |
------------------------------------------------------------------------------

Observe all federal, state and local regulations when storing this substance.
Store in accordance with 40 CFR 165 recommended procedures for the disposal
and storage of pesticides and pesticide containers.
Store away from incompatible substances.
Threshold Planning Quantity (TPQ):
The Superfund Amendments and Reauthorization Act (SARA) Section 302 requires
that each facility where any extremely hazardous substance is present in a
quantity equal to or greater than the TPQ established for that substance
notify the state emergency response commission for the state in which it is
located. Section 303 of SARA requires these facilities to participate in local
emergency response planning (40 CFR 355.30).

------------------------------------------------------------------------------
| SECTION 8        EXPOSURE CONTROLS/PERSONAL PROTECTION                     |
------------------------------------------------------------------------------

EXPOSURE LIMITS:

CHLORPYRIFOS:
  0.2 mg/m3 OSHA TWA (skin)
  0.2 mg/m3 ACGIH TWA (skin)
  1 pound CERCLA Section 103 Reportable Quantity
**OSHA revoked the final rule limits of January 19, 1989 in response to the
  11th Circuit Court of Appeals decision (AFL-CIO v. OSHA) effective
  June 30, 1993. See 29 CFR 1910.1000 (58 FR 35338)**

VENTILATION:
Provide local exhaust or process enclosure ventilation to meet published
exposure limits.

EYE PROTECTION:
Employee must wear splash-proof or dust-resistant safety goggles and a
faceshield to prevent contact with this substance.
Emergency wash facilities:
Where there is any possibility that an employee's eyes and/or skin may be
exposed to this substance, the employer should provide an eye wash fountain
and quick drench shower within the immediate work area for emergency use.

CLOTHING:
Employee must wear appropriate protective (impervious) clothing and equipment
to prevent any possibility of skin contact with this substance.












                                                  PST04910     Page 006 of 010
GLOVES:
Employee must wear appropriate protective gloves to prevent contact with this
substance.

RESPIRATOR:
The following respirators are recommended based on information found in the
  physical data, toxicity and health effects sections. They are ranked in
  order from minimum to maximum respiratory protection.
The specific respirator selected must be based on contamination levels found
  in the work place, must be based on the specific operation, must not exceed
  the working limits of the respirator and must be jointly approved by the
  National Institute for Occupational Safety and Health and the Mine Safety
  and Health Administration (NIOSH-MSHA).
  Any type 'C' supplied-air respirator with a full facepiece operated in
    pressure-demand or other positive pressure mode or with a full facepiece,
    helmet or hood operated in continuous-flow mode.
  Any self-contained breathing apparatus with a full facepiece operated in
    pressure-demand or other positive pressure mode.

FOR FIREFIGHTING AND OTHER IMMEDIATELY DANGEROUS TO LIFE OR HEALTH CONDITIONS:
  Any self-contained breathing apparatus that has a full facepiece and is
    operated in a pressure-demand or other positive-pressure mode.
  Any supplied-air respirator that has a full facepiece and is operated in a
    pressure-demand or other positive-pressure mode in combination with an
    auxiliary self-contained breathing apparatus operated in pressure-demand
    or other positive-pressure mode.

------------------------------------------------------------------------------
| SECTION 9           PHYSICAL AND CHEMICAL PROPERTIES                       |
------------------------------------------------------------------------------

DESCRIPTION: White crystalline solid with a mild mercaptan odor
MOLECULAR WEIGHT: 350.57
MOLECULAR FORMULA: C9-H11-CL3-N-O3-P-S
MELTING POINT: 106-108 F (41-42 C)
VAPOR PRESSURE: 0.0000187 mmHg 25 C
SPECIFIC GRAVITY: 1.398 @ 43 C
WATER SOLUBILITY: 2 ppm @ 25 C
SOLVENT SOLUBILITY: Soluble in acetone, benzene, chloroform, ethanol,
isooctane, methanol, and organic solvents

------------------------------------------------------------------------------
| SECTION 10              STABILITY AND REACTIVITY                           |
------------------------------------------------------------------------------

REACTIVITY:
May undergo violent exothermic decomposition above 130 C (266 F). The increase
in temperature and pressure may result in the violent rupture of the
container.

CONDITIONS TO AVOID:
None reported.











                                                  PST04910     Page 007 of 010
INCOMPATIBILITIES:

CHLORPYRIFOS:
  ALKALINE CONDITIONS: May cause hydrolysis.
  BRASS: May be corroded.
  COPPER: May be corroded.

HAZARDOUS DECOMPOSITION:
Thermal decomposition may release toxic and/or hazardous gases.

POLYMERIZATION:
Hazardous polymerization has not been reported to occur under normal
temperatures and pressures.

------------------------------------------------------------------------------
| SECTION 11               TOXICOLOGY INFORMATION                            |
------------------------------------------------------------------------------

CHLORPYRIFOS:

TOXICITY DATA: >200 mg/m3/4 hours inhalation-rat LC50; 2000 mg/kg
  skin-rabbit LD50; 202 mg/kg skin-rat LD50; 300 mg/kg oral-man
  TDLo; 82 mg/kg oral-rat LD50; 60 mg/kg oral-mouse LD50; 1000 mg/kg
  oral-rabbit LD50; 504 mg/kg oral-guinea pig LD50; 100 mg/kg
  subcutaneous-guinea pig LDLo; 192 mg/kg intraperitoneal-mouse LD50; 150
  mg/kg unreported-rat LD50; 163 mg/kg unreported-mammal LD50; mutagenic data
  (RTECS); reproductive effects data (RTECS).

CARCINOGEN STATUS: None.
LOCAL EFFECTS: Irritant- skin, eye.
ACUTE TOXICITY LEVEL: Toxic by ingestion; moderately toxic by dermal
  absorption.
TARGET EFFECTS: Cholinesterase inhibitor.
AT INCREASED RISK FROM EXPOSURE: Persons with respiratory ailments, recent
  exposure to cholinesterase inhibitors or impaired cholinesterase production,
  or liver malfunction.*
ADDITIONAL DATA: May cross the placenta. High environmental temperatures or
  exposure of the chemical to visible or ultraviolet light may enhance the
  toxicity. Interactions with medications may occur.*
* May be based on general information on organophosphates.

HEALTH EFFECTS

INHALATION:
CHLORPYRIFOS:
  See information on organophosphates.
ORGANOPHOSPHATES:

CHOLINESTERASE INHIBITOR.
  ACUTE EXPOSURE- When inhaled, the first effects of cholinesterase
    inhibitors are usually respiratory and may include nasal hyperemia
    and watery discharge, cough, chest discomfort, dyspnea, and wheezing due
    to increased bronchial secretions and bronchoconstriction. If sufficient
    amounts are absorbed, other systemic effects may begin within a few
    minutes or be delayed for up to 12 hours. Symptoms may include pallor,
    nausea, vomiting, diarrhea, abdominal cramps, headache, dizziness, ocular
    pain, blurred vision, miosis or in some cases, especially initially,
    mydriasis, lacrimation, salivation, sweating, and confusion. Other
    reported central nervous system or neuromuscular effects may include
    ataxia, slurred speech, areflexia, weakness, fatigue, fasciculations,
    twitching, tremors possibly of the tongue and eyelids, and eventually
    paralysis of the extremities and possibly of the respiratory muscles.

                                                  PST04910     Page 008 of 010

    In severe cases there may also be involuntary defecation and urination,
    cyanosis, psychosis, hyperglycemia, acute pancreatitis, cardiac
    irregularities, pulmonary edema, unconsciousness, convulsions, and coma.
    Death is primarily due to respiratory failure, although cardiovascular
    effects including cardiac arrest may also be implicated. Long term
    sequelae are rare but may include neuropsychiatric disorders and myopathy
    with muscle tenderness.
  CHRONIC EXPOSURE- Repeated or prolonged exposure may result in the effects
    of acute exposure. Other effects reported in workers repeatedly exposed
    include impaired memory and concentration, acute psychosis, severe
    depressions, irritabilty, confusion, apathy, emotional lability, social
    withdrawal, confusion, headache, speech difficulties, delayed reaction
    times, spatial disorientation, nightmares, sleepwalking, and drowsiness
    or insomnia. An influenza-like condition with headache, nausea, weakness,
    anorexia and malaise has also been reported.

SKIN CONTACT:
CHLORPYRIFOS:
IRRITANT.
  May cause irritation. Four doses of 25 mg/kg applied to the skin of humans
  for 12 hours each produced depressed plasma cholinesterase levels. See
  information on orhanophosphates.

ORGANOPHOSPHATES:
CHOLINESTERASE INHIBITOR.
  ACUTE EXPOSURE- Localized sweating and fasciculations may occur at the site
    of contact. If sufficient amounts are absorbed, other effects of
    cholinesterase inhibition as described in acute inhalation may occur.
    Symptoms may be delayed 2-3 hours, but usually no more than 12 hours.
    The rate of absorption is increased by the presence of dermatitis or high
    ambient temperatures.
  CHRONIC EXPOSURE- Repeated or prolonged exposure may cause effects as
    described in acute exposure. Some organophosphates may cause
    sensitization.
EYE CONTACT:
CHLORPYRIFOS:
IRRITANT.
  May cause irritation. See information on organophosphates.
ORGANOPHOSPHATES:

CHOLINESTERASE INHIBITOR.
  ACUTE EXPOSURE- Direct contact may cause pain, hyperemia, lacrimation,
    twitching of the eyelids, miosis, and ciliary muscle spasm with loss of
    accomodation, blurred or dimmed vision and browache. Sometimes mydriasis
    may occur instead of miosis. With sufficient exposure, other symptoms
    of cholinesterase inhibition as described in acute inhalation may occur.
  CHRONIC EXPOSURE- Repeated or prolonged exposure may cause effects as
    described in acute exposure. Some compounds have caused toxic effects on
    the crystalline lens, conjunctival thickening and obstruction of the
    nasolacrimal canals when used as miotic eyedrops.

INGESTION:
CHLORPYRIFOS:

TOXIC.
  A dose of 0.1 mg/kg ingested daily for four weeks produced significant
  cholinesterase inhibition in several human volunteers. In a delayed
  neurotoxicity study in hens, the results were negative. Fetotoxicity and





                                                  PST04910     Page 009 of 010

  fetal developmental abnormalities were observed in a chronic ingestion study
  of pregnant mice, but the same dose produced severe maternal toxicity. See
  information on organophosphates.
ORGANOPHOSPHATES:
CHOLINESTERASE INHIBITOR.
  ACUTE EXPOSURE- When ingested, the first effects may be nausea, vomiting,
    anorexia, abdominal cramps and diarrhea. Gastrointestinal absorption may
    cause the symptoms of cholinesterase inhibition as described in acute
    inhalation. Symptoms may begin within minutes or be delayed.
  CHRONIC EXPOSURE- Repeated ingestion may cause effects as described in
    acute exposure.

------------------------------------------------------------------------------
| SECTION 12               ECOLOGICAL INFORMATION                            |
------------------------------------------------------------------------------

ENVIRONMENTAL IMPACT RATING (0-4): no data available
ACUTE AQUATIC TOXICITY: no data available
DEGRADABILITY: no data available
LOG BIOCONCENTRATION FACTOR (BCF): no data available
LOG OCTANOL/WATER PARTITION COEFFICIENT: no data available

------------------------------------------------------------------------------
| SECTION 13                DISPOSAL INFORMATION                             |
------------------------------------------------------------------------------

Observe all federal, state and local regulations when disposing of this
substance.
Disposal must be in accordance with 40 CFR 165 Recommended Procedures for the
disposal and storage of pesticides and pesticide containers.

------------------------------------------------------------------------------
| SECTION 14             TRANSPORTATION INFORMATION                          |
------------------------------------------------------------------------------

U.S. DEPARTMENT OF TRANSPORTATION SHIPPING NAME-ID NUMBER, 49 CFR 172.101:
Organophophorus pesticides, solid, toxic, n.o.s.-UN 2783
U.S. DEPARTMENT OF TRANSPORTATION HAZARD CLASS OR DIVISION, 49 CFR 172.101:
6.1 - Poisonous materials
U.S. DEPARTMENT OF TRANSPORTATION PACKING GROUP, 49 CFR 172.101:
PG II
U.S. DEPARTMENT OF TRANSPORTATION LABELING REQUIREMENTS, 49 CFR 172.101
  AND SUBPART E:
Poison
U.S. DEPARTMENT OF TRANSPORTATION PACKAGING AUTHORIZATIONS:
EXCEPTIONS: None
NON-BULK PACKAGING: 49 CFR 173.212
BULK PACKAGING: 49 CFR 173.242
U.S. DEPARTMENT OF TRANSPORTATION QUANTITY LIMITATIONS 49 CFR 172.101:
PASSENGER AIRCRAFT OR RAILCAR: 25 kg












                                                  PST04910     Page 010 of 010

CARGO AIRCRAFT ONLY: 100 kg

------------------------------------------------------------------------------
| SECTION 15               REGULATORY INFORMATION                            |
------------------------------------------------------------------------------

TSCA STATUS: N
CERCLA SECTION 103 (40CFR302.4):     Y            1  POUND RQ
SARA SECTION 302 (40CFR355.30):      N
SARA SECTION 304 (40CFR355.40):      N
SARA SECTION 313 (40CFR372.65):      N
OSHA PROCESS SAFETY (29CFR1910.119): N
CALIFORNIA PROPOSITION 65:           N
SARA HAZARD CATEGORIES, SARA SECTIONS 311/312 (40 CFR 370.21)
ACUTE HAZARD:                Y
CHRONIC HAZARD:              Y
FIRE HAZARD:                 N
REACTIVITY HAZARD:           Y
SUDDEN RELEASE HAZARD:       N

------------------------------------------------------------------------------
| SECTION 16                        OTHER                                    |
------------------------------------------------------------------------------

  COPYRIGHT  1984-1995  MDL INFORMATION SYSTEMS, INC.  ALL RIGHTS RESERVED.